We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LMB:NASDAQLimbach Holdings, Inc. Analysis

Data as of 2026-04-15 - not real-time

$87.73

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Limbach Holdings (LMB) is trading at $87.73, comfortably above its 20‑day ($79.85) and 50‑day ($84.68) simple moving averages but still below the 200‑day SMA ($95.65), indicating short‑term strength within a longer‑term bearish backdrop. The MACD is bullish (line positive, histogram +1.19) and RSI sits at 60, while volume is tapering and 30‑day volatility is elevated at 52.8%, signaling a potentially choppy price action near the identified resistance of $88.23.
Fundamentally, the company posted 30% YoY revenue growth, a forward EPS of $4.96 and a forward P/E of 17.7 versus the industry average of 31.2, suggesting a growth‑oriented valuation advantage. Nevertheless, the DCF fair value of $76.3 is well below the market price, debt‑to‑equity is high at 28.5%, and the historical max drawdown exceeds 55%, highlighting valuation and balance‑sheet risks. Recent earnings disclosed record revenue and EBITDA, and a strategic pivot toward large, mission‑critical customers spurred a 3.3% price jump and underpins a consensus “buy” rating with a median target of $115, implying roughly 30% upside.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price flirting with resistance at $88.23
  • Bullish MACD but decreasing volume
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 30% revenue growth and strong forward earnings outlook
  • Strategic shift to mission‑critical customers
  • Analyst consensus target price ~30% above current level

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF fair value markedly below market price
  • Elevated debt‑to‑equity and historical drawdown risk
  • Sustained growth potential in the building‑systems niche

Key Metrics & Analysis

Financial Health

Revenue Growth30.10%
Profit Margin6.04%
P/E Ratio27.2
ROE22.38%
ROA8.77%
Debt/Equity28.55
P/B Ratio5.2
Op. Cash Flow$45.7M
Free Cash Flow$25.2M
Industry P/E31.2

Technical Analysis

TrendBearish
RSI60.5
Support$69.58
Resistance$88.22
MA 20$79.85
MA 50$84.68
MA 200$95.65
MACDBullish
VolumeDecreasing
Fear & Greed Index88.64

Valuation

Fair Value$76.29
Target Price$116.60
Upside/Downside32.91%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.35
Volatility52.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.